What is Intensity Therapeutics, Inc. Common stock?
, a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 8.19M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.